In hepatocellular carcinoma, STAT5A/5B/6 were suggested to be potential prognostic markers.[21] Moreover, STAT5B/6 could be potential biomarkers for the prognosis of non-small cell lung cancer.[22] Another study indicated that low STAT5B expression was associated with a poor overall survival of ovarian cancer patients.[23] Moreover, STAT5B was a prognostic biomarker for chronic lymphocytic leukemia.[24] Another study suggested STAT5B as prognostic biomarker for renal cell carcinoma.[25]. Here, STAT5B is linked to renal cell carcinoma.